{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:43:49Z","timestamp":1790747029802,"version":"4.1.0"},"reference-count":48,"publisher":"China Science Publishing & Media Ltd.","issue":"6","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province","award":["2015-110"],"award-info":[{"award-number":["2015-110"]}]},{"name":"Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province","award":["2015-287"],"award-info":[{"award-number":["2015-287"]}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["201801D121202"],"award-info":[{"award-number":["201801D121202"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["201701D121085"],"award-info":[{"award-number":["201701D121085"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31170748"],"award-info":[{"award-number":["31170748"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.1093\/abbs\/gmaa038","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T11:12:07Z","timestamp":1585739527000},"page":"612-619","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP\/PKA\/RhoA\/ROCK2 signaling"],"prefix":"10.3724","volume":"52","author":[{"given":"Shaohua","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianfeng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2020,5,9]]},"reference":[{"key":"null","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/cphy.c140055","volume":"6","author":"Tanai E","year":"2015","unstructured":"Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol, 2015, 6: 187-214.","journal-title":"Compr Physiol"},{"key":"null","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","volume":"385","author":"Braunwald E","year":"2015","unstructured":"Braunwald E. The war against heart failure: the Lancet lecture. Lancet, 2015, 385: 812-824.","journal-title":"Lancet"},{"key":"null","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ehjci\/jev155","volume":"17","author":"D'Ascenzi F","year":"2016","unstructured":"D'Ascenzi F, Pelliccia A, Corrado D, Cameli M, Curci V, Alvino F, Natali BM. Right ventricular remodelling induced by exercise training in competitive athletes. Eur Heart J Cardiovasc Imaging, 2016, 17: 301-307.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"null","doi-asserted-by":"crossref","first-page":"a2467","DOI":"10.1136\/bmj.a2467","volume":"337","author":"Driver JA","year":"2008","unstructured":"Driver JA, Djousse L, Logroscino G, Gaziano JM, Kurth T. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ, 2008, 337:","journal-title":"BMJ"},{"key":"null","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","volume":"128","author":"Bernardo BC","year":"2010","unstructured":"Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther, 2010, 128: 191-227.","journal-title":"Pharmacol Ther"},{"key":"null","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"Baggio LL","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007, 132: 2131-2157.","journal-title":"Gastroenterology"},{"key":"null","first-page":"217","volume":"62","author":"Scheen AJ","year":"2007","unstructured":"Scheen AJ. Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes. Rev Med Liege, 2007, 62: 217-221.6.","journal-title":"Rev Med Liege"},{"key":"null","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40519-016-0352-y","volume":"22","author":"Guglielmi V","year":"2017","unstructured":"Guglielmi V, Sbraccia P. GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products. Eat Weight Disorder, 2017, 22: 231-240.","journal-title":"Eat Weight Disorder"},{"key":"null","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"Nikolaidis LA","year":"2004","unstructured":"Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004, 109: 962-965.","journal-title":"Circulation"},{"key":"null","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"Sokos GG","year":"2006","unstructured":"Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail, 2006, 12: 694-699.","journal-title":"J Card Fail"},{"key":"null","doi-asserted-by":"crossref","first-page":"889","DOI":"10.33549\/physiolres.933558","volume":"66","author":"Palee S","year":"2017","unstructured":"Palee S, Chattipakorn SC, Chattipakorn N. Liraglutide preserves intracellular calcium handling in isolated murine myocytes exposed to oxidative stress. Physiol Res, 2017, 66: 889-895.","journal-title":"Physiol Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"e005146","DOI":"10.1161\/CIRCIMAGING.116.005146","volume":"9","author":"Chen WR","year":"2016","unstructured":"Chen WR, Chen YD, Tian F, Yang N, Cheng LQ, Hu SY, Wang J. Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Imaging, 2016, 9:","journal-title":"Circ Cardiovasc Imaging"},{"key":"null","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"Ban K","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008, 117: 2340-2350.","journal-title":"Circulation"},{"key":"null","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/hrt.2010.219345","volume":"98","author":"Read PA","year":"2012","unstructured":"Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart, 2012, 98: 408-413.","journal-title":"Heart"},{"key":"null","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.4161\/cc.21088","volume":"11","author":"David M","year":"2012","unstructured":"David M, Petit D, Bertoglio J. Cell cycle regulation of Rho signaling pathways. Cell Cycle, 2012, 11: 3003-3010.","journal-title":"Cell Cycle"},{"key":"null","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1152\/physrev.2001.81.3.999","volume":"81","author":"Berk BC","year":"2001","unstructured":"Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev, 2001, 81:","journal-title":"Physiol Rev"},{"key":"null","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.3485309","volume":"232","author":"Berk BC","year":"1986","unstructured":"Berk BC, Alexander RW, Brock TA, Gimbrone MA, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science, 1986, 232: 87-90.","journal-title":"Science"},{"key":"null","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.HYP.9.6_Pt_2.III181","volume":"9","author":"Griendling KK","year":"1987","unstructured":"Griendling KK, Berk BC, Ganz P, Jr GM, Alexander RW. Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism. State of the art lecture. Hypertension, 1987, 9: 181-185.","journal-title":"Hypertension"},{"key":"null","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/01.HYP.0000100443.09293.4F","volume":"42","author":"Yoshihiro T","year":"2003","unstructured":"Yoshihiro T, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension, 2003, 42:","journal-title":"Hypertension"},{"key":"null","first-page":"960","volume":"17","author":"An L","year":"2019","unstructured":"An L, An S, Jia Z, Wang H, Yang Z, Xu C, Teng X. Atorvastatin improves left ventricular remodeling and cardiac function in rats with congestive heart failure by inhibiting RhoA\/rho kinase-mediated endothelial nitric oxide synthase. Exp Ther Med, 2019, 17: 960-966.","journal-title":"Exp Ther Med"},{"key":"null","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2018.07.016","volume":"276","author":"Liu Z","year":"2018","unstructured":"Liu Z, Zhang M, Zhou T, Shen Q, Qin X. Exendin-4 promotes the vascular smooth muscle cell re-differentiation through AMPK\/SIRT1\/FOXO3a signaling pathways. Atherosclerosis, 2018, 276:","journal-title":"Atherosclerosis"},{"key":"null","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1039\/C6FO01842D","volume":"8","author":"Ming D","year":"2017","unstructured":"Ming D, Song YL, Ya WC, Na Z, Jing M, Zhao WX, Ye L. Trans-Polydatin protects the mouse heart against ischemia\/reperfusion injury via inhibition of the renin-angiotensin system (RAS) and Rho kinase (ROCK) activity. Food Funct, 2017, 8: 2309-2321.","journal-title":"Food Funct"},{"key":"null","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/jcb.27386","volume":"120","author":"Yan X","year":"2019","unstructured":"Yan X, Jiao K, Song X. Shen'ge powder decreases the cardiomyocyte hypertrophy in chronic heart failure by activating the Rho protein\/Rho-associated coiledcoil forming protein kinase signaling pathway. J Cell Biochem, 2019, 120: 3038-3045.","journal-title":"J Cell Biochem"},{"key":"null","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/HYPERTENSIONAHA.116.08662","volume":"69","author":"Zhou Q","year":"2017","unstructured":"Zhou Q, Wei SS, Wang H, Wang Q, Li W, Li G, Hou JW. Crucial role of ROCK2-mediated phosphorylation and upregulation of FHOD3 in the pathogenesis of angiotensin II-induced cardiac hypertrophy. Hypertension, 2017, 69: 1070-1083.","journal-title":"Hypertension"},{"key":"null","doi-asserted-by":"crossref","first-page":"E7129","DOI":"10.1073\/pnas.1721298115","volume":"115","author":"Sunamura S","year":"2018","unstructured":"Sunamura S, Satoh K, Kurosawa R, Ohtsuki T, Kikuchi N, Elias-Al-Mamun M, Shimizu T. Different roles of myocardial ROCK1 and ROCK2 in cardiac dysfunction and postcapillary pulmonary hypertension in mice. Proc Natl Acad Sci U S A, 2018, 115: E7129-e7138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"null","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2337\/db12-1025","volume":"62","author":"Wang D","year":"2013","unstructured":"Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP\/PKA\/Rho-dependent mechanism. Diabetes, 2013, 62: 1697-1708.","journal-title":"Diabetes"},{"key":"null","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1210\/en.2014-1314","volume":"155","author":"Kong X","year":"2014","unstructured":"Kong X, Yan D, Sun J, Wu X, Mulder H, Hua X, Ma X. Glucagon-like peptide 1 stimulates insulin secretion via inhibiting RhoA\/ROCK signaling and disassembling glucotoxicity-induced stress fibers. Endocrinology, 2014, 155: 4676-4685.","journal-title":"Endocrinology"},{"key":"null","first-page":"692","volume":"73","author":"Xiong QF","year":"2018","unstructured":"Xiong QF, Fan SH, Zhang X, Niu Y, Li XW, Shi YW, Zhang LH. GLP-1 attenuates Ang II-induced proliferation and migration in rat aorta smooth muscle cells via inhibition of the RhoA\/ROCK2 signaling pathway. Pharmazie, 2018, 73: 692-699.","journal-title":"Pharmazie"},{"key":"null","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"Drucker DJ","year":"2016","unstructured":"Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab, 2016, 24: 15-30.","journal-title":"Cell Metab"},{"key":"null","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"Shimizu I","year":"2016","unstructured":"Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol, 2016, 97: 245-262.","journal-title":"J Mol Cell Cardiol"},{"key":"null","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tips.2008.05.003","volume":"29","author":"Marchesi C","year":"2008","unstructured":"Marchesi C, Paradis P, Schiffrin EL. Role of the renin\u2013angiotensin system in vascular inflammation. Trends Pharmacol Sci, 2008, 29: 367-374.","journal-title":"Trends Pharmacol Sci"},{"key":"null","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"Mehta PK","year":"2007","unstructured":"Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol, 2007, 292:","journal-title":"Am J Physiol Cell Physiol"},{"key":"null","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10557-015-6592-7","volume":"29","author":"Zhang LH","year":"2015","unstructured":"Zhang LH, Pang XF, Bai F, Wang NP, Shah AI, Mckallip RJ, Li XW. Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT 1 \/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc Drugs Ther, 2015, 29: 243-255.","journal-title":"Cardiovasc Drugs Ther"},{"key":"null","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bbrc.2015.09.179","volume":"468","author":"Zhou Y","year":"2015","unstructured":"Zhou Y, He X, Chen Y, Huang Y, Wu L, He J. Exendin-4 attenuates cardiac hypertrophy via AMPK\/mTOR signaling pathway activation. Biochem Biophys Res Commun, 2015, 468: 394-399.","journal-title":"Biochem Biophys Res Commun"},{"key":"null","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jphs.2017.05.012","volume":"135","author":"Li J","year":"2017","unstructured":"Li J, Yuan YP, Xu SC, Zhang N, Xu CR, Wan CX, Ren J. Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways. J Pharmacol Sci, 2017, 135: 97-104.","journal-title":"J Pharmacol Sci"},{"key":"null","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1002\/jcb.27268","volume":"119","author":"Hong L","year":"2018","unstructured":"Hong L, Lai HL. Silencing CTGF\/CCN2 inactivates the MAPK signaling pathway to alleviate myocardial fibrosis and left ventricular hypertrophy in rats with dilated cardiomyopathy. J Cell Biochem, 2018, 119: 9519-9531.","journal-title":"J Cell Biochem"},{"key":"null","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.yjmcc.2018.07.250","volume":"121","author":"Li RL","year":"2018","unstructured":"Li RL, Wu SS, Wu Y, Wang XX, Chen HY, Xin JJ, Li H. Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway. J Mol Cell Cardiol, 2018, 121: 242-255.","journal-title":"J Mol Cell Cardiol"},{"key":"null","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/abbs\/gmv111","volume":"47","author":"Xie F","year":"2015","unstructured":"Xie F, Liu W, Feng F, Li X, He L, Lv D, Qin X. Apelin-13 promotes cardiomyocyte hypertrophy via PI3K-Akt-ERK1\/2-p70S6K and PI3K-induced autophagy. Acta Biochim Biophys Sin (Shanghai), 2015, 47: 969-980.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"null","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11010-017-2944-x","volume":"429","author":"Gao L","year":"2017","unstructured":"Gao L, Yao R, Liu Y, Wang Z, Huang Z, Du B, Zhang D. Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway. Mol Cell Biochem, 2017, 429: 167-177.","journal-title":"Mol Cell Biochem"},{"key":"null","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3389\/fphar.2018.00896","volume":"9","author":"Qian W","year":"2018","unstructured":"Qian W, Yu D, Zhang J, Hu Q, Tang C, Liu P, Ye P. Wogonin attenuates isoprenaline-induced myocardial hypertrophy in mice by suppressing the PI3K\/Akt pathway. Front Pharmacol, 2018, 9:","journal-title":"Front Pharmacol"},{"key":"null","first-page":"3217","volume":"9","author":"Al-Rasheed NM","year":"2015","unstructured":"Al-Rasheed NM, Al-Oteibi MM, Al-Manee RZ, Al-Shareef SA, Al-Rasheed NM, Hasan IH, Mohamad RA. Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK\/STAT pathway. Drug Des Devel Ther, 2015, 9: 3217-3229.","journal-title":"Drug Des Devel Ther"},{"key":"null","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MAJ.0b013e31822993ff","volume":"343","author":"Chang L","year":"2012","unstructured":"Chang L, Yang R, Wang M, Liu J, Wang Y, Zhang H, Li Y. Angiotensin II type-1 receptor-JAK\/STAT pathway mediates the induction of visfatin in angiotensin II-induced cardiomyocyte hypertrophy. Am J Med Sci, 2012, 343: 220-226.","journal-title":"Am J Med Sci"},{"key":"null","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.intimp.2017.05.002","volume":"48","author":"Zhao L","year":"2017","unstructured":"Zhao L, Wu D, Sang M, Xu Y, Liu Z, Wu Q. Stachydrine ameliorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through inhibiting NF-kappaB and JAK\/STAT signaling pathways in rats. Int Immunopharmacol, 2017, 48: 102-109.","journal-title":"Int Immunopharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/diabetes.48.10.1979","volume":"48","author":"Flamez D","year":"1999","unstructured":"Flamez D, Gilon P, Moens K, Van Breusegem A, Delmeire D, Scrocchi LA, Henquin JC. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes, 1999, 48: 1979-1986.","journal-title":"Diabetes"},{"key":"null","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lfs.2018.09.013","volume":"211","author":"Khedr RM","year":"2018","unstructured":"Khedr RM, Ahmed AAE, Kamel R, Raafat EM. Sitagliptin attenuates intestinal ischemia\/reperfusion injury via cAMP\/PKA, PI3K\/Akt pathway in a glucagon-like peptide 1 receptor-dependent manner. Life Sci, 2018, 211: 31-39.","journal-title":"Life Sci"},{"key":"null","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2013-03-487850","volume":"122","author":"Aburima A","year":"2013","unstructured":"Aburima A, Wraith KS, Raslan Z, Law R, Magwenzi S, Naseem KM. cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway. Blood, 2013, 122: 3533-3545.","journal-title":"Blood"},{"key":"null","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbrc.2015.11.065","volume":"469","author":"Sun S","year":"2016","unstructured":"Sun S, Zhang M, Lin J, Hu J, Zhang R, Li C, Wei T. Lin28a protects against diabetic cardiomyopathy via the PKA\/ROCK2 pathway. Biochem Biophys Res Commun, 2016, 469: 29-36.","journal-title":"Biochem Biophys Res Commun"},{"key":"null","first-page":"1693","volume":"41","author":"Chang G","year":"2018","unstructured":"Chang G, Liu J, Qin S, Jiang Y, Zhang P, Yu H, Lu K. Cardioprotection by exenatide: a novel mechanism via improving mitochondrial function involving the GLP-1 receptor\/cAMP\/PKA pathway. Int J Mol Med, 2018, 41: 1693-1703.","journal-title":"Int J Mol Med"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/10126056D78E4D5DB5EFF97A914A7510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmaa038","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/abbs\/article-pdf\/52\/6\/612\/33458367\/gmaa038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/10126056D78E4D5DB5EFF97A914A7510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T05:55:37Z","timestamp":1666245337000},"score":1,"resource":{"primary":{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmaa038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,5,9]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abbs\/gmaa038","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}